An analyst from Deutsche Bank maintained Novo Nordisk B (CSE: NOVOb) at 'buy' with a price target of DKK1450.00. Prior to this rating, Novo Nordisk B had 14 buy ratings, 3 hold ratings,...
Novo Nordisk NVO has entered into exclusive negotiations to acquire a controlling stake in French medical device maker Biocorp in a deal that values Biocorp at 154.4 million euros, or about...
Teens and older adults at risk, say doctors and researchers, as Novo Nordisk’s Wegovy and Ozempic are hyped heavily online.
An analyst from UBS maintained Novo Nordisk B (CSE: NOVOb) at 'sell' with a price target of DKK720.00 from a prior price target of DKK680.00. Prior to this rating, Novo Nordisk B had 14...
Novo Nordisk A/S (NYSE: NVO) announced headline results from OASIS 1 Phase 3a trial in the global OASIS program. OASIS 1 is a 68-week, efficacy, and safety trial comparing once-daily oral...
Danuglipron, made by Pfizer could offer an advantage as an oral treatment option for weight loss over a frequent injection of Ozempic, made by Novo Nordisk.
Researchers at the Mayo Clinic found that Novo Nordisk A/S's (NYSE: NVO) Wegovy (semaglutide) reduced the risk of heart disease and boosted weight loss. After a year of taking semaglutide,...
CEOs of Eli Lilly And Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and PBM executives from Cigna Group's (NYSE: CI) Express Scripts, and UnitedHealth Group...
He was the only executive to do so before a Senate Health Committee hearing that also included the CEOs of Novo Nordisk and Sanofi.
Boehringer Ingelheim and Zealand Pharma A/S (OTC: ZLDPF) announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose....
An analyst from Morgan Stanley maintained Novo Nordisk B (CSE: NOVOb) at to 'overweight' and a price target of DKK1160.00 from a prior price target of DKK1130.00. Prior to this rating,...
Novo Nordisk A/S (NYSE: NVO) reported Q1 FY23 sales of DKK 53.37 billion, up 27% Y/Y (+25% on constant currency). Earlier this month, the Denmark-based company significantly raised its...
A Barclays analyst maintained Novo Nordisk B (CSE: NOVOb) at Overweight and a price target of $1350.00 from a prior price target of DKK1200.00. Prior to this rating, Novo Nordisk B had 15...
A Jefferies analyst maintained Novo Nordisk B (CSE: NOVOb) at Underperform and a price target of $850.00 from a prior price target of DKK730.00. Prior to this rating, Novo Nordisk B had...
A Deutsche Bank analyst maintained Novo Nordisk B (CSE: NOVOb) at Buy and a price target of $1450.00 from a prior price target of DKK1200.00. Prior to this rating, Novo Nordisk B had 15...
A Stifel analyst maintained Novo Nordisk B (CSE: NOVOb) at Buy and a price target of $1280.00 from a prior price target of DKK1205.00. Prior to this rating, Novo Nordisk B had 15 buy...
A Morgan Stanley analyst maintained Novo Nordisk B (CSE: NOVOb) at Overweight and a price target of $1130.00 from a prior price target of DKK1050.00. Prior to this rating, Novo Nordisk B...
A Berenberg analyst maintained Novo Nordisk B (CSE: NOVOb) at Hold and a price target of $950.00 from a prior price target of DKK810.00. Prior to this rating, Novo Nordisk B had 14 buy...
A Citi analyst maintained Novo Nordisk B (CSE: NOVOb) at Buy and a price target of $1200.00. Prior to this rating, Novo Nordisk B had 14 buy ratings, 4 hold ratings, and 4 sell...
A Deutsche Bank analyst maintained Novo Nordisk B (CSE: NOVOb) at Buy and a price target of $1200.00. Prior to this rating, Novo Nordisk B had 14 buy ratings, 4 hold ratings, and 4 sell...
A Morgan Stanley analyst maintained Novo Nordisk B (CSE: NOVOb) at Overweight and a price target of $1050.00. Prior to this rating, Novo Nordisk B had 14 buy ratings, 4 hold ratings, and...
(Adds close of U.S. markets) * MSCI's all-country world index gains 0.5% * Silver rebounds, Brent crude prices at 11-month high By Herbert Lash NEW YORK, Feb 3 (Reuters) - Global equities...
* Milan stocks rise on hopes of Draghi becoming next PM* Daimler jumps on plan to spin-off truck business* GSK slides; warns of bigger than expected fall in 2021 earnings(Updates to...
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)Feb 3 (Reuters) - European shares rose for the third session on Wednesday as focus...
(For a live blog on European stocks, type LIVE/ in an Eikon news window)* STOXX 600 records second week of gains* Pandora jumps as online demand boosts sales* Europe records 100,000 daily...
(For a live blog on European stocks, type LIVE/ in an Eikon news window) Oct 9 (Reuters) - European stock markets gained on Friday on rosy earnings forecasts from retailers Pandora and...
(Adds gold, oil settlement prices)By Herbert LashNEW YORK, May 6 (Reuters) - Oil prices slid and world equity markets seesawed on Wednesday as investor hopes for a pickup in business...
(Adds close of European market)By Herbert LashNEW YORK, May 6 (Reuters) - Oil prices slid and world equity markets seesawed on Wednesday as investor hopes for a pickup in business activity...
(Adds U.S. market open, byline, dateline; previous LONDON)* Grim PMI data in EuropeBy Herbert Lash and Tom ArnoldNEW YORK/LONDON, May 6 (Reuters) - World equity markets were mixed on...
* European Commission sees record euro zone recession in 2020* Healthcare stocks steady on AstraZeneca boost* Risk seen that PEPP might be challenged - Economist* Oil and gas sector leads...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
